论文部分内容阅读
目的比较CAG方案和Ara-c加MIT或HHT或VP-16治疗难治性急性髓细胞白血病的疗效。方法将50例难治性急性髓细胞白血病患者分成2组,CAG组30例、HAE(MAE)组20例,分别使用以上2种方案进行化疗,比较2组的临床疗效及不良反应。结果CAG组、HAE组2个疗程CR率为75%和45%,2组有显著性差异。总有效率分别为80%和55%,2组比较无显著性差异。CAG方案治疗过程中不良反应非常少见,主要是血液学异常,粒缺和血小板减少,70%~80%超过NCI毒性Ⅱ级。结论CAG在难治性复发性患者治疗上均有其推广价值。尤其适用外周血白细胞低,骨髓增生低下患者,生活质量较高。
Objective To compare the efficacy of CAG regimen with Ara-c plus MIT or HHT or VP-16 in the treatment of refractory acute myeloid leukemia. Methods Fifty patients with refractory acute myeloid leukemia were divided into two groups: 30 in CAG group and 20 in HAE (MAE) group. The above two regimens were used for chemotherapy. The clinical efficacy and adverse reactions in the two groups were compared. Results The CR rates of two courses in CAG group and HAE group were 75% and 45%, respectively. There were significant differences between the two groups. The total effective rate was 80% and 55% respectively, there was no significant difference between the two groups. Adverse reactions during CAG regimen were rare, mainly hematologic abnormalities, granulomaremia and thrombocytopenia, with 70% -80% exceeding NCI toxicity grade II. Conclusion CAG in the treatment of refractory recurrent patients have its value in the promotion. Especially for low peripheral blood leukocytes, bone marrow hyperplasia in patients with lower quality of life higher.